AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier
Le stock est insuffisant. unités ont été rajoutées au panier
En rupture de stock
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
photos non contractuelles
Product description: Monoclonal Antibody. Recognizes the Human protein. Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. Ubiquitin+1 (Ub+1) is a novel mutant form of ubiquitin that can be produced through a process known as molecular frameshift. Ub+1 can be polyubiquitinated to produce aberrant polyubiquitin chains that inhibit the 26S proteasome. Especially ub+1 is accumulated in aggregates containing amyloid-beta and phosphorylated-tau. Elevated expression of Ub+1 mRNA and protein has been observed in the brains of patients with Alzheimer's disease. Also ub +1 acts as an aggravating factor in polyglutamine-induced neuro-degeneration. Protein modifier which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Attachment to proteins as a Lys-48-linked polymer usually leads to their degradation by proteasome. Attachment to proteins as a monomer or as an alternatively linked polymer does not lead to proteasomal degradation and may be required for numerous functions, including maintenance of chromatin structure, regulation of gene expression, stress response, ribosome biogenesis and DNA repair.
Alternate Names/Synonyms: UB+1; Frameshift
Product Type: Monoclonal Antibody
Isotype: Mouse IgG1 kappa
Immunogen: Synthetic peptide (KLH coupled) corresponding to C-terminal residues of human Ubiquitin +1.
Applications: IP, WB
Species Crossreactivity: Human
Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Short Term Storage: +4°C
Long Term Storage: -20°C
Shipping: BLUE ICE
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.
Literature References: 1) Van Leeuwen, F.W. et al. (1998) Science, 279, 242-247. (General)2) Van Leeuwen, F.W. et al. (1998) Trends Neurosci. 21(8), 331-335. (General)
Veuillez saisir les champs obligatoires!